Ratings LUMIBIRD

Equities

LBIRD

FR0000038242

Real-time Euronext Paris Other stock markets 04:46:30 2024-05-07 am EDT			5-day change	1st Jan Change
13 ^EUR	+0.78%		+4.42%	+6.73%

May. 03	Lumibird launches product for dry eyes	CF
Apr. 23	Lumibird: over 7% growth in quarterly sales	CF

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
LUMIBIRD	+6.73%	307M	-
THERMO FISHER SCIENTIFIC	+8.06%	219B	B
DANAHER CORPORATION	+6.94%	183B	B-
INTUITIVE SURGICAL, INC.	+13.54%	136B	B-
SIEMENS HEALTHINEERS AG	-4.26%	63.07B	A-
EDWARDS LIFESCIENCES CORPORATION	+11.59%	51.28B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.76%	52.55B	B+
AGILENT TECHNOLOGIES, INC.	+1.14%	41.21B	A
GE HEALTHCARE TECHNOLOGIES INC.	+3.21%	36.43B	-
RESMED, INC.	+26.11%	31.87B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes